Financial performance 2008/2007
Download Excel table (see terms of use page)
OUR FINANCIAL PERFORMANCE| 2008 | 2007 | 2006 | 2008 compared to 2007 | 2007 compared to 2006 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| |
Sales $m |
CER growth $m |
Growth due to exchange effect $m |
Sales $m |
CER growth $m |
Growth due to exchange effect $m |
Sales $m |
CER growth % |
Reported growth % |
CER growth % |
Reported growth % |
| Seroquel | 4,452 | 346 | 79 | 4,027 | 526 | 85 | 3,416 | 9 | 11 | 15 | 18 |
| Diprivan | 278 | (3) | 18 | 263 | (53) | 12 | 304 | (1) | 6 | (17) | (13) |
| Zomig | 448 | (3) | 17 | 434 | 18 | 18 | 398 | (1) | 3 | 5 | 9 |
| Local anaesthetics | 605 | 13 | 35 | 557 | (6) | 34 | 529 | 2 | 9 | (1) | 5 |
| Other | 54 | (7) | 2 | 59 | (1) | 3 | 57 | (12) | (8) | (2) | 4 |
| Total | 5,837 | 346 | 151 | 5,340 | 484 | 152 | 4,704 | 6 | 9 | 10 | 14 |
PERFORMANCE 2008
Reported performance
Neuroscience sales grew by 9% to $5,837 million in 2008 from $5,340 million in 2007. All geographic areas experienced growth and Seroquel grew strongly by 11%.
Performance – CER growth rates
Sales in the Neuroscience therapy area grew by 6% to $5,837 million from $5,340 million last year.
US sales for Seroquel for the full year were $3,015 million, 5% ahead of last year. Seroquel remains the market leader in the US anti-psychotic market, with a total prescription share of 31.6% in December 2008.
For the full year, Seroquel sales in the Rest of World increased by 17% to $1,437 million, with value and volume growth well ahead of the market in all regions.
Sales of Zomig for the full year were up 6% in the US to $187 million. Sales in the Rest of World were down 5% to $261 million.
PERFORMANCE 2007
Reported performance
Sales in the Neuroscience therapy area rose by 14% in 2007, up to $5,340 million from $4,704 million in 2006. Seroquel was the principal driver of performance, recording an 18% increase in sales.
Performance – CER growth rates
Neuroscience sales grew by 10% at CER. Annual Seroquel sales exceeded $4 billion for the first time in 2007. Full year sales were $4,027 million, up 15% over last year. In the US, Seroquel sales increased by 15% to $2,863 million. Seroquel sales in other markets were up 16% for the full year, as a result of market share gain in most markets.
Zomig sales for the full year increased 5% in the US (to $177 million) and 4% in other markets, totalling $434 million.
